secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001193125-26-086629
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx reports FY2025 net loss of $144.7M; avexitide Phase 3 enrollment complete, topline data Q3 2026
--------------------------------------------------------------------------------

- Net loss for FY2025: $144.7M ($1.53/share) vs $301.7M ($4.43/share) in FY2024.
- Phase 3 LUCIDITY trial of avexitide in PBH enrollment complete; topline data expected Q3 2026, potential launch 2027.
- Cash, equivalents, and short-term investments $317.0M at Dec 31, 2025; cash runway into 2028.
- R&D expenses decreased to $90.4M from $104.1M due to lower AMX0035 spending, offset by increased avexitide costs.
- Selected AMX0318 (GLP-1 receptor antagonist) as development candidate for PBH; IND filing targeted 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526086629/0001193125-26-086629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526086629/amlx-20260303.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-086629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer